Owlstone Medical announces $27 million USD first close in series E financing round

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round.

AI advances could revolutionize hepatocellular carcinoma diagnosis

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is a major global health concern with rising rates, particularly in North Africa

December 29, 2023

Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST

Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a

May 11, 2024

Almonds can be part of a healthy weight loss diet, research shows

When it comes to weight loss, nuts can get a bad rap – while they’re high in protein, they’re also high in fats, and this

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.